Experimental arthritis: JAK inhibition with tofacitinib curbs RANKL-induced joint damage

Nature Reviews Rheumatology

Volumn 8, Issue 10, 2012, Pages 564-

  Onuora, Sarah ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD68 ANTIGEN; INTERLEUKIN 6; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 3; JANUS KINASE INHIBITOR; OSTEOCLAST DIFFERENTIATION FACTOR; TOFACITINIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTHROPATHY; CD4+ T LYMPHOCYTE; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; NONHUMAN; NOTE; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; RAT; RHEUMATOID ARTHRITIS;

EID: 84867035032     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2012.147     Document Type: Note

References (1)

1. LaBranche, T.P.et al.JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production.Arthritis Rheum.doi:10.1002/art.34649